Vaccination Against Extracellular Vimentin Plus Doxorubicin for Canine Hemangiosarcoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26189096 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Diederik J M Engbersen und 9 weiteren Autor:innen. Beteiligte Einrichtung: CimCure BV, 1066 CX Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Doxorubicin, Hemangiosarcoma, Dog Diseases, Vimentin. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU Eurostars project SimPro, Dutch Cancer Society.
Abstract (Originalsprache)
Angiosarcomas are highly aggressive soft tissue tumors with poor prognosis in both humans and dogs. In dogs, visceral hemangiosarcoma offers a relevant spontaneous model for evaluating novel therapies. Surgery alone yields a median survival of 1–3 months, and treatment with doxorubicin (DOX), alone or in combination (e.g., with propranolol), modestly extends median survival time to 5–7 months, with a 1-year survival of around 10%. We developed a conjugate vaccine technology, called immune Boost (iBoost), and hypothesized that combining DOX with an iBoost vaccine targeting extracellular vimentin (eVim) could improve survival without added toxicity. Twenty-three dogs with visceral hemangiosarcoma received six cycles of DOX every two weeks post-splenectomy, alongside four doses every other week of eVim iBoost immunotherapy, followed by maintenance vaccinations every two months. Outcomes were compared to historical controls treated with DOX alone. Compared to the control group the median overall survival time increased from 136 to 235 days (NS), restricted mean survival time at one year increased with 81 days (p = 0.02) and 1-year survival rate was 44% versus 14% (p = 0.0344). The combination was well-tolerated, with no systemic vaccine-related toxicity. Adding dog eVim vaccine to DOX appears to improve survival without added toxicity in dogs with hemangiosarcoma. These results support further clinical development, including evaluation in human angiosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CimCure BV, 1066 CX Amsterdam, The Netherlands.
- Department of Pathology, Leiden University Medical Center, 2333 ZG Leiden, The Netherlands.
- IVC Animal Hospital Barendrecht, 2992 LC Barendrecht, The Netherlands.
- IVC Animal Hospital Nieuwegein, 3433 NP Nieuwegein, The Netherlands.
- Angiogenesis Laboratory, Department of Medical Oncology, Amsterdam University Medical Center, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands.
- Flint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
ORCID-Profile: Diederik J M Engbersen, Elisabeth J M Huijbers, Pancras C W Hogendoorn, Douglas H Thamm, Arjan W Griffioen
Förderung
- EU Eurostars project SimPro
- Dutch Cancer Society
Zitieren
APA
Engbersen, D. J. M., van Bergen, L., Bos, E. N., Hansen, Q., Roos, A., Huijbers, E. J. M., Faulhaber, E. A., Hogendoorn, P. C. W., Thamm, D. H., & Griffioen, A. W. (2025). Vaccination Against Extracellular Vimentin Plus Doxorubicin for Canine Hemangiosarcoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26189096
Vancouver
Engbersen DJM, van Bergen L, Bos EN, Hansen Q, Roos A, Huijbers EJM, et al. Vaccination Against Extracellular Vimentin Plus Doxorubicin for Canine Hemangiosarcoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26189096
BibTeX
@article{Engbersen2025,
author = {Engbersen, Diederik J M and van Bergen, Lobke and Bos, Emma N and Hansen, Quinty and Roos, Arno and Huijbers, Elisabeth J M and Faulhaber, Erica A and Hogendoorn, Pancras C W and Thamm, Douglas H and Griffioen, Arjan W},
title = {Vaccination Against Extracellular Vimentin Plus Doxorubicin for Canine Hemangiosarcoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26189096}
}
EUVIMED